Features
IL-6 Inhibition as a Treatment for Noninfectious Uveitis
Understanding interleukin-6 signaling sheds light on novel biologics that could benefit patients with refractory NIU.
By Naveen Karthik, MD, Dilraj S. Grewal, MD, FASRS
Expanding the Role of Suprachoroidal Injections
Clinical data support this targeted route for small molecules, gene therapy, and oncologic agents, with a good safety profile and potential to reduce treatment burden.
By Thomas A. Ciulla, MD, MBA
Incorporating AI Into Global ROP Care
Advances in imaging and machine learning offer new opportunities to standardize diagnosis and improve access worldwide.
By Amy Song, BA, Noelle Whitestone, MHA, Karyn E. Jonas, MSN, et al.
Brachytherapy for Uveal Melanoma: Is the Dose Too High?
Lower radiation doses and personalized plaque design could balance tumor control with vision preservation.
By Jose J. Echegaray, MD, Soumaya Bouhout, MD, Arun D. Singh, MD
Web Exclusives
Diagnosis and Management of Retinal Vasoproliferative Tumors
Early recognition and timely intervention are critical for preventing vision loss from VPTs.
By Arun D. Singh, MD, Soumaya Bouhout, MD
Departments
Reflections from ASRS
Upfront: This issue features articles on ocular oncology, pediatric retina, and emerging treatments for uveitis.
By Diana V. Do, MD
The Port Delivery System in the Paradigm
Controversies in Care: Experts assess the current role and future potential of Genentech’s Susvimo in patient care.
By Michael Colucciello, MD, Dante J. Pieramici, MD, FASRS, Carl C. Awh, MD
Uveitis Coding Considerations
Coding: Accurate documentation and coding are necessary to reflect the variable presentation of uveitis and its systemic associations.
By Elizabeth Cifers, MBA, MSW, CHC, CPC
Clinical Trial Update September 2025
Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.
News
GLP-1RAs Linked to Reduced Uveitis Risk
A large cohort study suggests uveitis risk is lower in patients taking GLP-1 receptor agonists, compared to other antihyperglycemic drugs.
By Jim Gallagher, senior managing editor
BVI Introduces Virtuoso at Euretina
The dual-function phaco-vitrectomy device has not yet received regulatory clearance.
Prithvi Ramtohul Receives Tadayoni Award
The award, established in memory of the late Ramin Tadayoni, MD, PhD, and presented at Euretina, supports talented retina researchers with a significant grant.
Initial DIAMOND Results Support OCS-01 Efficacy
Data on patients with DME, reported at Euretina, show BCVA gains and improvement in retinal thickness at 12 weeks.
Head-to-Head Trial Compares Iluvien and Anti-VEGF
Patients with diabetic macular edema who received the Iluvien implant needed less than half as many injections as those treated with aflibercept alone.
Study Connects Iron Regulation and Vision Loss
Data presented at the Euretina congress in Paris highlight transferrin’s potential role in dry AMD progression.
Migaldendranib Demonstrates Efficacy in DME and nAMD
Phase 2 results presented at Euretina showed reduced injection frequency as well as improvements in retinal structure and visual function.
Usher 1B Gene Therapy Shows Functional Improvements
Updated phase 1/2 data presented at Euretina suggest AAVantgarde's AAVB-081 may improve measures of vision.
Euretina 2025 Opens With Record Attendance
The European Society of Retina Specialists welcomed more than 10,000 participants to its 25th annual congress.
Consensus Group Advocates Shift in GA Care
European retina experts call for multimodal imaging, early specialist referral, and strategies that address the broader impact of geographic atrophy on patients’ quality of life.
ZEISS Introduces High-Speed TDC Veloce Cutter
At Euretina 2025, the company presented a new vitreoretinal cutter and highlighted updates to its visualization and diagnostic technologies.
SALWEEN Results Show Durable PCV Treatment
In data presented at Euretina 2025, more than half of Asian patients with polypoidal choroidal vasculopathy required fewer injections after a year of Vabysmo therapy.
Supported Content
Two Specialties, One System
How UNITY VCS Is Transforming Ophthalmic Surgery at Duke Eye Center
By Dr. Kourtney Houser, Dr. Lejla Vajzovic